A phase I, randomized, double-blind, multiple-ascending-dose study to evaluate the safety and pharmacokinetics of GDC-5780 in healthy subjects
Latest Information Update: 13 Dec 2023
At a glance
- Drugs GDC-5780 (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 06 Dec 2023 Status changed from active, no longer recruiting to completed.
- 10 Mar 2023 New trial record
- 06 Mar 2023 Status changed from not yet recruiting to recruiting.